Xian Zeng

• CellectLNP is a versatile platform for modular engineering of antibody-conjugated LNPs to achieve efficient and selective in vivo CAR cmRNA delivery to T cells
• cmCAR, a prolonged and enhanced CAR expression platform enabled by scarless circular mRNA technology, exhibits superior efficiency for in vivo engineering of CAR-T cells
• Robust anti-cancer activity and profound B cell-depletion in humanized mouse models and non-human primates by in vivo circular mRNA CAR, providing novel opportunities for cancers and autoimmune diseases

The Asian biopharmaceutical sector is thriving in RNA innovation, manufacturing advancements and strategic alliances to enhance the knowledge, skills, and experience across the region to become the powerhouse of commercial success. Hear from pioneering executive leaders across mRNA and next generation RNAs who will discuss their ambitions, strategies and challenges for the future of this technology, the hottest indications of unmet need and progress towards the next commercial approval.

• What are the future opportunities, promising targets and applications on the horizon for RNA therapeutics, vaccines and gene editing tools to achieve clinical success?
• How to develop and de-risk RNA platforms in the competitive Asian and Pacific markets
• What are the biggest challenges to overcome when it comes to science vs strategy and pipeline management for 2025/26?